Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy regimen consisting of anthracycline chemotherapy drugs and glucocorticoid medications. Anthracyclines (such as doxorubicin, daunorubicin, epirubicin, and idarubicin) work by intercalating with DNA and interfering with DNA metabolism and RNA production, primarily through inhibition of topoisomerase II. Glucocorticoids (such as prednisone and dexamethasone) play an essential role in treating acute lymphoblastic leukemia (ALL). This combination is particularly used in the treatment of leukemias, especially acute lymphoblastic leukemia (ALL), where glucocorticoids are typically given for 4 consecutive weeks in combination with vincristine, an anthracycline, asparaginase, and intrathecal chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anthracycline + glucocorticoid.